Skip to main content
Christine (Megerdichian) Parseghian, MD, Oncology, Houston, TX

Christine Lisa (Megerdichian) Parseghian MD


Physician

Join to View Full Profile
  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Dr. Parseghian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2012 - 2015
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 2012, MD

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - Present
  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2027
  • GA State Medical License
    GA State Medical License 2023 - 2027
  • TN State Medical License
    TN State Medical License 2023 - 2027
  • LA State Medical License
    LA State Medical License 2023 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Circulating tumor DNA (ctDNA) heterogeneity as first- and third-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
  • Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Dad Diagnosed with Colorectal Cancer at 38 Recalls Early Symptoms: ‘Something’s Not Right’
    Dad Diagnosed with Colorectal Cancer at 38 Recalls Early Symptoms: ‘Something’s Not Right’April 3rd, 2025
  • The Use of Research Biopsies in Oncology Trials: Challenges and Controversies
    The Use of Research Biopsies in Oncology Trials: Challenges and ControversiesMarch 1st, 2019
  • Open-Label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination with Defactinib (FAK Inhibitor) and Cetuximab in Patients with Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
    Open-Label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination with Defactinib (FAK Inhibitor) and Cetuximab in Patients with Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerApril 17th, 2024

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: